257 related articles for article (PubMed ID: 17253919)
1. Posaconazole as salvage therapy in a patient with disseminated zygomycosis: case report and review of the literature.
Page RL; Schwiesow J; Hilts A
Pharmacotherapy; 2007 Feb; 27(2):290-8. PubMed ID: 17253919
[TBL] [Abstract][Full Text] [Related]
2. Posaconazole pharmacokinetics in a 2-year-old boy with rhino-cerebral-orbital zygomycosis.
Egelund EF; Egelund TA; Ng JS; Wassil SK; Peloquin CA
Pharmacotherapy; 2013 Jan; 33(1):e1-8. PubMed ID: 23307552
[TBL] [Abstract][Full Text] [Related]
3. Zygomycosis over-infection during voriconazole therapy for aspergillosis in a heart transplant patient, successfully treated with liposomal amphotericin and posaconazole.
Bourke P; Castro P; Rabagliati R; Beltran C; Verdejo H; Winter JL; Bourge RC
Transpl Infect Dis; 2012 Oct; 14(5):E56-9. PubMed ID: 22852999
[TBL] [Abstract][Full Text] [Related]
4. Treatment of zygomycosis: current and new options.
Rogers TR
J Antimicrob Chemother; 2008 Jan; 61 Suppl 1():i35-40. PubMed ID: 18063603
[TBL] [Abstract][Full Text] [Related]
5. Current experience in treating invasive zygomycosis with posaconazole.
Cornely OA; Vehreschild JJ; Rüping MJ
Clin Microbiol Infect; 2009 Oct; 15 Suppl 5():77-81. PubMed ID: 19754763
[TBL] [Abstract][Full Text] [Related]
6. [Invasive zygomycosis in patients treated for haematological malignancies].
Verweij PE; van der Velden WJ; Donnelly JP; Blijlevens NM; Warris A
Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2597-602. PubMed ID: 18161258
[TBL] [Abstract][Full Text] [Related]
7. ZYGOMYCOSIS: current approaches to management of patients with haematological malignancies.
Pagano L; Valentini CG; Caira M; Fianchi L
Br J Haematol; 2009 Sep; 146(6):597-606. PubMed ID: 19466966
[TBL] [Abstract][Full Text] [Related]
8. Posaconazole: an extended-spectrum triazole antifungal agent.
Schiller DS; Fung HB
Clin Ther; 2007 Sep; 29(9):1862-86. PubMed ID: 18035188
[TBL] [Abstract][Full Text] [Related]
9. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases.
van Burik JA; Hare RS; Solomon HF; Corrado ML; Kontoyiannis DP
Clin Infect Dis; 2006 Apr; 42(7):e61-5. PubMed ID: 16511748
[TBL] [Abstract][Full Text] [Related]
10. Posaconazole as salvage therapy for zygomycosis.
Greenberg RN; Mullane K; van Burik JA; Raad I; Abzug MJ; Anstead G; Herbrecht R; Langston A; Marr KA; Schiller G; Schuster M; Wingard JR; Gonzalez CE; Revankar SG; Corcoran G; Kryscio RJ; Hare R
Antimicrob Agents Chemother; 2006 Jan; 50(1):126-33. PubMed ID: 16377677
[TBL] [Abstract][Full Text] [Related]
11. Rhino-cerebral zygomycosis resistant to antimycotic treatment: a case report.
Vyzantiadis TA; Kioumi A; Papadakis E; Braimi M; Dermitzakis E; Tsitouridis I; Antoniadis A
Mycoses; 2009 Jan; 52(1):87-90. PubMed ID: 18498302
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo activities of posaconazole against zygomycetes with various degrees of susceptibility.
Spreghini E; Orlando F; Giannini D; Barchiesi F
J Antimicrob Chemother; 2010 Oct; 65(10):2158-63. PubMed ID: 20667887
[TBL] [Abstract][Full Text] [Related]
13. Posaconazole: a next-generation triazole antifungal.
Farowski F; Vehreschild JJ; Cornely OA
Future Microbiol; 2007 Jun; 2(3):231-43. PubMed ID: 17661696
[TBL] [Abstract][Full Text] [Related]
14. Periorbital zygomycosis (mucormycosis) treated with posaconazole.
Rutar T; Cockerham KP
Am J Ophthalmol; 2006 Jul; 142(1):187-188. PubMed ID: 16815283
[TBL] [Abstract][Full Text] [Related]
15. Disseminated zygomycosis with involvement of the central nervous system.
Skiada A; Vrana L; Polychronopoulou H; Prodromou P; Chantzis A; Tofas P; Daikos GL
Clin Microbiol Infect; 2009 Oct; 15 Suppl 5():46-9. PubMed ID: 19754757
[TBL] [Abstract][Full Text] [Related]
16. Posaconazole as first line treatment for disseminated zygomycosis.
Peel T; Daffy J; Thursky K; Stanley P; Buising K
Mycoses; 2008 Nov; 51(6):542-5. PubMed ID: 18422921
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of combined surgery and antifungal therapies for the management of invasive zygomycoses in patients with haematological malignancies.
Valentini CG; Candoni A; Fianchi L; Posteraro B; Simeone E; Costa F; Sanguinetti M; Voso MT; Caira M; Fanin R; Pagano L
Mycoses; 2010 Jan; 53(1):89-92. PubMed ID: 19207832
[TBL] [Abstract][Full Text] [Related]
18. Posaconazole: clinical pharmacology and potential for management of fungal infections.
Groll AH; Walsh TJ
Expert Rev Anti Infect Ther; 2005 Aug; 3(4):467-87. PubMed ID: 16107193
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment of pulmonary zygomycosis with posaconazole in a recipient of a haploidentical donor stem cell transplant.
Gilman AL; Serrano A; Skelley J; Zwick D
Pediatr Blood Cancer; 2006 Dec; 47(7):959-63. PubMed ID: 16123983
[TBL] [Abstract][Full Text] [Related]
20. Mucor circinelloides as a cause of invasive maxillofacial zygomycosis: an emerging dimorphic pathogen with reduced susceptibility to posaconazole.
Khan ZU; Ahmad S; Brazda A; Chandy R
J Clin Microbiol; 2009 Apr; 47(4):1244-8. PubMed ID: 19171681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
